Home/Filings/4/0001209191-21-018326
4//SEC Filing

SCHIERMEIER ANDREW 4

Accession 0001209191-21-018326

CIK 0001652130other

Filed

Mar 4, 7:00 PM ET

Accepted

Mar 5, 5:53 PM ET

Size

8.2 KB

Accession

0001209191-21-018326

Insider Transaction Report

Form 4
Period: 2021-03-03
SCHIERMEIER ANDREW
EVP, Dev and Corp Strategy
Transactions
  • Award

    Stock Option (right to buy)

    2021-03-03+78,75078,750 total
    Exercise: $57.71Exp: 2031-03-02Common Stock (78,750 underlying)
  • Award

    Restricted Stock Unit

    2021-03-03+13,12513,125 total
    Common Stock (13,125 underlying)
Footnotes (2)
  • [F1]This option was granted on March 3, 2021 with respect to 78,750 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
  • [F2]On March 3, 2021, the reporting person was granted 13,125 Restricted Stock Units ("RSUs") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments.

Issuer

Intellia Therapeutics, Inc.

CIK 0001652130

Entity typeother

Related Parties

1
  • filerCIK 0001738456

Filing Metadata

Form type
4
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 5:53 PM ET
Size
8.2 KB